Core Viewpoint - The dispute between Guizhou BaiLing and Huachuang Securities, which began as a cooperation to alleviate financial difficulties, has escalated into a legal battle over control and financial obligations, with both parties presenting conflicting claims regarding the management and control of the company [1][3][40]. Group 1: Background of the Dispute - In 2019, Guizhou BaiLing's controlling shareholder Jiang Wei introduced Huachuang Securities as a rescue partner due to high debt and stock pledge rates, leading to a financial arrangement involving 1.4 billion yuan and stock pledges [4][40]. - Huachuang Securities provided 1.4 billion yuan through two asset management plans and acquired 161 million shares, representing 11.54% of Guizhou BaiLing's total shares [5][40]. - The two parties agreed to a strategic partnership, with Huachuang Securities stating it would not seek control over Guizhou BaiLing [7][42]. Group 2: Legal Proceedings and Claims - Huachuang Securities filed a lawsuit against Jiang Wei and others, claiming repayment of the 1.4 billion yuan principal and 361 million yuan from stock pledges, along with interest and penalties [1][3][45]. - Jiang Wei has accused Huachuang Securities of attempting to gain control over Guizhou BaiLing under the guise of financial assistance, leading to regulatory investigations [3][38]. - The legal dispute has reached the courts, with Huachuang Securities asserting its claims while Jiang Wei counters with allegations of misconduct by Huachuang Securities [1][3][48]. Group 3: Financial Implications - As of December 3, Guizhou BaiLing's stock price was 5.57 yuan per share, with a total market capitalization of 7.785 billion yuan, while the shares involved in the dispute were valued at approximately 1.944 billion yuan, exceeding the 1.761 billion yuan in claims [12][46]. - The financial arrangements included additional collateral, such as properties and receivables, to secure the investments made by Huachuang Securities [11][45]. - The ongoing litigation poses significant financial risks for Huachuang Securities, as the outcome will impact its asset quality and risk management practices [35].

①濮阳开州投资集团拟发行8亿元公司债，获上交所通过； ②因涉嫌内幕交易等，贵州百灵实控人姜伟被证监会立案； 实习编辑:金怡杉 | 审核:李震 | 监审:古筝 ③星宇股份筹划发行H股股票并在港交所上市； ④德固特终止筹划重大资产重组事项； ⑤国发股份董事长姜烨因个人原因辞任，辞任后不再担任该公司及控股子公司任何职务； ⑥山西汾酒股东华创鑫睿减持计划实施完毕，共减持1620万股该公司股份，占该公司总股本的1.33%； ⑦唯赛勃控股股东香港唯赛勃拟减持不超过520万股该公司股份，即不超过该公司总股本的2.99%； ⑧腾景科技股东福建华兴拟减持不超过254.03万股该公司股份，即不超过该公司总股本的1.96%； ⑨长盈通董事柳祎因个人原因辞职，辞职后不再担任该公司任何职务； ⑩因近期市场波动较大，开滦集团决定取消发行"25开滦MTN006"。 #成为立方风控鸟会员，尊享直播版风控服务# ...

贵州百灵此前披露的简历显示，姜伟，男，1961年出生，1982年毕业于贵阳中医学院药学系，大学文化，高级工程师。历任安顺制药厂 厂长、贵州百灵制药有限公司董事长、贵州百灵企业集团制药有限公司董事长、贵州百灵董事长。 资料显示，贵州百灵是一家集苗药研发、生产、销售于一体的医药上市公司，独家苗药产品银丹心脑通软胶囊、咳速停糖浆及胶囊和非 苗药产品金感胶囊、维C银翘片、小儿柴桂退热颗粒等都为公司主要盈利产品。公司于2010年6月3日在深交所上市。 2025年前三季度，公司营业收入为21.02亿元，同比下降24.28%；归母净利润为5681.44万元，同比下降35.60%；扣非归母净利润为 2120.99万元，同比下降16.72%。 12月3日晚间，贵州百灵（002424）公告称，公司收到公司实际控制人姜伟的通知，其于近日收到中国证监会下发的《立案告知书》。 按照该告知书，姜伟因涉嫌内幕交易、信息披露违法、违反限制性规定转让股票，中国证监会决定对其进行立案。 贵州百灵表示，本次立案系对公司实际控制人姜伟个人的调查，与公司日常经营管理和业务活动无关，不会对上市公司及子公司生产经 营活动产生影响。立案调查期间，姜伟将积极 ...

Core Viewpoint - Guizhou BaiLing announced that its actual controller, Jiang Wei, received a notice from the China Securities Regulatory Commission (CSRC) regarding an investigation into insider trading and information disclosure violations [1][3]. Group 1: Company Overview - Jiang Wei holds 245.35 million shares of Guizhou BaiLing, accounting for 17.55% of the total share capital, and is the largest shareholder [3][10]. - Jiang Wei's shares are currently 100% pledged, and he has been actively cooperating with the CSRC during the investigation [3][10]. Group 2: Financial Performance - For the period from January to September, Guizhou BaiLing reported revenue of 2.102 billion yuan, a decrease of 24.28% year-on-year, and a net profit of 56.81 million yuan, down 35% [7][13]. - In the third quarter alone, the company achieved revenue of 640 million yuan, an increase of 1.11% year-on-year, and a net profit of 4.98 million yuan, up 559.9% [7][13]. Group 3: Regulatory Issues - In August 2024, the company faced public reprimands from the Shenzhen Stock Exchange for failing to disclose its 2023 annual performance forecast, which indicated a net loss of 415 million yuan [6][12]. - The CSRC issued a formal notice of investigation to Jiang Wei in November 2024 for alleged violations related to information disclosure [6][12].

Core Viewpoint - The actual controller of Guizhou Bailing, Jiang Wei, has been placed under investigation by the China Securities Regulatory Commission (CSRC) for insider trading, information disclosure violations, and illegal stock transfers [6][8]. Group 1: Investigation Details - On December 3, Guizhou Bailing announced that Jiang Wei received a notice of investigation from the CSRC due to allegations of insider trading and information disclosure violations [6]. - The investigation is focused on Jiang Wei personally and is stated to have no impact on the company's daily operations or business activities [6]. - Guizhou Bailing has been previously investigated for information disclosure violations, with the CSRC launching an investigation in November 2024, the results of which are still pending [4][8]. Group 2: Company Background and Leadership - Guizhou Bailing was founded in 1999 and specializes in the research, production, and sales of traditional Chinese medicine, with notable products including "Yindan Xinnaotong Soft Capsules" and "Vitamin C Yinqiao Tablets" [10]. - Jiang Wei, born in 1961 and a graduate of Guizhou University of Traditional Chinese Medicine, has been the chairman of Guizhou Bailing since 2007 and led the company to become the first listed company in the traditional Chinese medicine sector in 2010 [7]. Group 3: Financial Performance - For the first three quarters of 2025, Guizhou Bailing reported a revenue of 2.102 billion yuan, a year-on-year decrease of 24.28%, and a net profit attributable to shareholders of 57 million yuan, down 35.6% year-on-year [14]. - As of December 3, the stock price of Guizhou Bailing was 5.57 yuan per share, with a total market capitalization of 7.785 billion yuan [14]. Group 4: Legal Disputes - Recent legal disputes involving Jiang Wei and Huachuang Securities have drawn significant attention, with Huachuang Securities filing lawsuits against Jiang Wei and others over a total amount of 1.4 billion yuan related to a rescue plan and stock pledge disputes [11]. - Jiang Wei has counter-sued, demanding that Huachuang Securities fulfill its obligations regarding the sale of pledged shares and compensation for losses incurred due to alleged malicious reporting [11].

Core Viewpoint - The actual controller of Guizhou Bailing, Jiang Wei, has been placed under investigation by the China Securities Regulatory Commission (CSRC) for insider trading, information disclosure violations, and illegal stock transfers [4][17]. Group 1: Investigation Details - Jiang Wei received a notice of investigation from the CSRC, which states that he is suspected of insider trading and violating information disclosure regulations [4][17]. - Guizhou Bailing clarified that the investigation pertains to Jiang Wei personally and will not affect the company's daily operations or business activities [4][17]. - The company will continue to monitor the situation and fulfill its information disclosure obligations as required by law [4][18]. Group 2: Background on Jiang Wei - Jiang Wei, born in 1961, graduated from Guizhou University of Traditional Chinese Medicine in 1982 and is currently the chairman of Guizhou Bailing [4][18]. - He has been instrumental in the company's development, leading the launch of several well-known traditional medicine products and overseeing its listing on the Shenzhen Stock Exchange in 2010 [4][18]. Group 3: Regulatory History - Guizhou Bailing has faced multiple regulatory actions in recent years, including corrective measures and warnings from the Guizhou Securities Regulatory Bureau due to issues with financial disclosures and internal controls [5][18]. - The company was previously investigated for information disclosure violations in November 2024, with the results of that investigation still pending [6][19]. Group 4: Legal Disputes - Jiang Wei is involved in a legal dispute with Huachuang Securities regarding a rescue plan and stock pledge disputes, with claims amounting to 1.4 billion yuan and 361 million yuan respectively [21][22]. - The disputes arose from allegations that Jiang Wei failed to fulfill obligations related to stock repurchase and repayment, leading to litigation [21][22]. - As of September 2025, Jiang Wei holds 17.55% of Guizhou Bailing's shares, while Huachuang Securities holds 11.54% through asset management plans [22]. Group 5: Financial Performance - For the first three quarters of 2025, Guizhou Bailing reported revenues of 2.102 billion yuan, a year-on-year decrease of 24.28%, and a net profit attributable to shareholders of 57 million yuan, down 35.6% year-on-year [23]. - As of December 3, 2025, the company's stock price was 5.57 yuan per share, with a total market capitalization of 7.785 billion yuan [24].

Core Viewpoint - Guizhou Bailing announced that its actual controller, Jiang Wei, is under investigation by the China Securities Regulatory Commission (CSRC) for insider trading and information disclosure violations, which is unrelated to the company's operations and will not impact its business activities [1][4]. Company Overview - Guizhou Bailing is engaged in the research, production, and sales of traditional Chinese medicine, with a registered capital of 1.4112 billion yuan and total assets of 7.059 billion yuan. The company was listed on the Shenzhen Stock Exchange in June 2010 and aims to strengthen its position in the traditional Chinese medicine sector [4][3]. Financial Performance - For the first three quarters of 2025, Guizhou Bailing reported revenue of 2.102 billion yuan, a year-on-year decrease of 24.28%, and a net profit attributable to shareholders of 57 million yuan, down 35.60% year-on-year [5]. - The company experienced a significant decline in revenue and net profit in the first half of 2025, with revenue of 1.462 billion yuan, a decrease of 31.77%, and a net profit of 52 million yuan, down 40.73% year-on-year. The decline in revenue from traditional Chinese medicine products, which account for over 80% of total revenue, was particularly notable, with a year-on-year decrease of 37.07% [4][5]. - Despite a year-on-year increase in revenue and net profit in the third quarter, the overall performance for the first three quarters remained significantly lower due to poor results in the first half of the year [4].

Group 1 - Dongfang Electric announced that three executives plan to reduce their holdings by a total of no more than 30,000 shares due to personal financial needs [1] - Yahu Pharmaceutical's APL-1401 clinical trial data was presented at the 19th European Colorectal Congress, indicating progress in treating moderate to severe ulcerative colitis [1] - Guizhou Bai Ling's actual controller is under investigation by the China Securities Regulatory Commission for insider trading and information disclosure violations [3] Group 2 - Bairen Medical's ePTFE pericardial membrane product has been approved for registration, ending the reliance on imports for this product in the domestic market [4] - Qianxin received approval for a total of 2 billion yuan in technology innovation bonds, with plans to issue medium-term notes and short-term financing bonds [6] - Tengjing Technology's shareholder plans to reduce holdings by no more than 1.96% of the company's shares [7] Group 3 - Yuntianhua's subsidiary is required to pay 386 million yuan in overdue taxes and penalties, which will impact the company's net profit for 2025 [8] - Jianyou Pharmaceutical's propofol emulsion injection has received FDA approval in the United States [9] - Suzhou Gaoxin successfully acquired land use rights for a residential project for 360 million yuan [9] Group 4 - Chalco International's subsidiary won a bid for a 3.03 billion yuan electrolytic aluminum project [11] - Tai Long Pharmaceutical's stock will continue to be suspended due to potential changes in control as the major shareholder is planning a share transfer [12] - Qianli Technology reported a 63.44% year-on-year increase in automobile sales for November, although new energy vehicle sales decreased by 43.98% [13] Group 5 - Fosun Pharma's innovative drug FXS0887 has received approval for a Phase I clinical trial for advanced malignant solid tumors [14] - Guoen Co. has obtained approval for a project to produce 20,000 square meters of aviation-grade acrylic glass, with a total investment of 560 million yuan [15] - Guofa Co.'s chairman resigned due to personal reasons [17] Group 6 - Shanghai Construction won a bid for a state-owned construction land use right for 264 million yuan [18] - Weixin Kang's subsidiary received approval for a clinical trial of lidocaine cream for local anesthesia [20] - Sanxing Medical's subsidiary is a candidate for a 152 million yuan transformer procurement project for the State Grid [20] Group 7 - People's Daily announced the resignation of its president due to work changes, while retaining other leadership roles [21] - Beibu Gulf Port reported a 0.29% year-on-year increase in cargo throughput for November [22] - Chongqing Construction won three engineering projects with a total value of approximately 2.773 billion yuan [23] Group 8 - Xingyu Co. is planning to issue H-shares and list on the Hong Kong Stock Exchange [24] - Huajian Group signed a design contract worth 160 million yuan for a comprehensive project [25] - Wankai New Materials plans to invest 350 million yuan in a technical transformation project for producing 100,000 tons of adipic acid [26] Group 9 - Kaipuyun received a government subsidy of 18 million yuan, which is 87.43% of its net profit for the last audited fiscal year [28] - Ningbo Port expects a 10.8% year-on-year increase in container throughput for November [30] - An Cai High-Tech plans to invest 498 million yuan to upgrade its photovoltaic glass production line [32] Group 10 - Shunhao Co. stated that its existing business has not generated synergies with the rail business, which faces various risks [34] - Yihualu plans to publicly transfer 35% of its stake in Liaoyun Company [35] - ST Wanfang's shareholder plans to reduce holdings by no more than 3% of the company's shares [36] Group 11 - Youyou Food's shareholder plans to reduce holdings by no more than 110,000 shares [38] - Hengtong Optic-Electric's incentive fund has spent 49.98 million yuan to purchase company shares [41] - Zoli Pharmaceutical plans to issue convertible bonds to raise no more than 1.556 billion yuan for various projects [42]

12月3日，贵州百灵公告，收到公司实际控制人姜伟的通知，其于近日收到中国证券监督管理委员会下 发的《立案告知书》。 按照该告知书，姜伟因涉嫌内幕交易、信息披露违法、违反限制性规定转让股票，根据《中华人民共和 国证券法》《中华人民共和国行政处罚法》等法律法规，中国证监会决定对其进行立案。 贵州百灵表示，本次立案系对公司实际控制人姜伟个人的调查，与公司日常经营管理和业务活动无关， 不会对上市公司及子公司生产经营活动产生影响。 贵州百灵今日收跌0.89%，报5.57元。 编 辑丨瑜见 ...

#贵州百灵实控人涉内幕交易等被证监会立案#【贵州百灵：因涉嫌内幕交易等，实控人姜伟被证监会立 案】贵州百灵公告，公司收到公司实际控制人姜伟的通知，其于近日收到中国证券监督管理委员会下发 的《立案告知书》。按照该告知书，姜伟因涉嫌内幕交易、信息披露违法、违反限制性规定转让股票， 根据《中华人民共和国证券法》《中华人民共和国行政处罚法》等法律法规，中国证监会决定对其进行 立案。本次立案系对公司实际控制人姜伟个人的调查，与公司日常经营管理和业务活动无关，不会对上 市公司及子公司生产经营活动产生影响。（第一财经） ...